



# Biotech Daily

Thursday September 7, 2017

*Daily news on ASX-listed biotechnology companies*

- \* **ASX FLAT, BIOTECH UP: ACTINOGEN UP 12%, REVA DOWN 4%**
- \* **EPAT PAIN DIAGNOSTIC 1<sup>st</sup> SALE TO DEMENTIA SUPPORT AUSTRALIA**
- \* **RECCE STARTS FDA APPLICATION FOR RECCE 327 ANTIBIOTIC**
- \* **ACTINOGEN: '1<sup>st</sup> PATIENT TREATED IN XANAMEM ALZHEIMER'S TRIAL'**
- \* **MESOBLAST'S PROF SILVIU ITESCU INCREASES, DILUTED TO 15%**

## MARKET REPORT

The Australian stock market was effectively unchanged on Thursday September 7, 2017 with the ASX200 up 0.2 points to 5,689.9 points.

Sixteen of the Biotech Daily Top 40 stocks were up, 13 fell, eight traded unchanged and three were untraded.

Actinogen was the best, up 0.6 cents or 12.2 percent to 5.5 cents with 385,834 shares traded.

LBT climbed 6.6 percent; Benitec, Cellmid, Oncosil and Psivida improved more than four percent; Airxpanders and ITL rose more than two percent; Avita, Bionomics, Impedimed, Neuren, Opthea, Orthocell and Starpharma were up more than one percent; with Nanosonics and Resmed up by less than one percent.

Reva led the falls, down three cents or 3.85 percent to 75 cents with 45,997 shares traded.

Admedus and Pro Medicus lost more than three percent; Acrux, Clinuvel, Compumedics and Osprey shed more than two percent; CSL, Medical Developments, Pharmaxis, Universal Biosensors and Viralytics were down more than one percent; with Cochlear, Mesoblast and Sirtex down by less than one percent.

## EPAT TECHNOLOGIES

Epat says it has signed its first commercial agreement for the clinical use of its pain assessment software application with Dementia Support Australia.

According to the Dementia Centre website, it was founded by the Sydney-based non-denominational Christian aged-care provider Hammond Care, with Dementia Support Australia part of its operations.

Epat said that Dementia Support Australia provided nationwide consultant support and advice to carers of people with dementia with behavioral and psychological symptoms of dementia impacting on their care.

The company said that the Federal Government-funded Dementia Support Australia had 150 clinical consultants covering community, residential and acute settings and the organization would use the Epat pain recognition application “as a first line pain assessment tool for [about] 5,000 people with dementia in Australia each year” in community, residential and acute settings.

Epat said the application would be used to perform a baseline pain assessment during the consultant’s first visit to a patient and be used on subsequent visits to perform follow-up pain assessments so that the changes in the patients’ pain levels and associated behaviours are recorded.

The company said that the roll-out would begin in Western Australia and South Australia from the end of the month and be fully embedded by April 2018.

Epat said the agreement would run until June 30, 2019 with maximum fees payable to Epat of \$40,000 a year.

Epat chief executive officer Philip Daffas said he was “delighted” to work with Dementia Support Australia to improve the quality of life for people with dementia in Australia.

“This agreement is core to accelerating the awareness and commercialization of the Epat [application] across approximately 1,300 residential aged care and home care providers supporting many of the 400,000 people with dementia in Australia,” Mr Daffas said.

Dementia Services Australia director Prof Colm Cunningham said the technology “allows our consultants, who have been called in to assist someone with dementia, to understand the cause of a perceived severe behavior, enabling them to quickly identify if that person is in pain”.

“An outcome of dementia can be a loss of ability to communicate and when that person is in pain it is sometimes displayed in frustration or behavior that is out of character,” Prof Cunningham said. “As a result, pain for people living with dementia may often go undetected or under-treated.”

Epat fell 0.7 cents or 8.6 percent to 7.4 cents with 8.7 million shares traded.

## RECCE

Recce says it has submitted pre-clinical data and related documentation to the US Food and Drug Administration for human clinical trials of its Recce 327 antibiotic.

Recce said that the standard response time for a pre-investigational new drug application submission was 60 days, including initial feedback.

The company said that it expected at least one more submission of data to support the final application for approval to begin human trials.

Recce said it was developing a new class of broad spectrum synthetic antibiotics to address the challenge of antibiotic resistant superbugs.

The company said Recce 327 had been developed to treat sepsis from Staphylococcus aureus and Escherichia coli bacteria, including their “superbug” or resistant forms.

Recce was unchanged at 16.5 cents.

## ACTINOGEN MEDICAL

Actinogen says it has completed the 12-week treatment and four-week follow-up of the first of 174 patients in its randomized phase II trial of Xanamem for Alzheimer's disease. Actinogen said that it did not know whether the patient received Xanamem or placebo but the completion of treatment was "another significant milestone" and the company was "very pleased with how the trial is progressing".

The company said that all 20 study sites in the US, the UK and Australia were open for recruitment and 26 patients had been enrolled.

Actinogen said that the study was on-track to enrol the last patient by the end of 2018 and produce top-line study results by April 2019.

Actinogen was up 0.6 cents or 12.2 percent to 5.5 cents.

## MESOBLAST

Mesoblast executive director Prof Silviu Itescu says he has increased his holding but been diluted from 68,244,642 shares (21.6%) to 68,958,928 shares (14.96%).

Prof Itescu said he acquired 714,286 shares for \$1,000,000 in the \$50.7 million one-for-12 entitlement offer at \$1.40 a share (BD: Aug 25, 2017).

Prof Itescu said he directly held 67,756,838 shares and a further 487,804 shares through Josaka Investments, with the 714,286 shares held by Tamit Nominees Pty Ltd.

Mesoblast fell one cent or 0.7 percent to \$1.50 with 1.1 million shares traded.